[Gene-based treatment in spinal muscular atrophy]

Area of Science:

• Neurology
• Genetics
• Pharmacology

Background:

• Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder affecting approximately 80-120 newborns annually.
• Characterized by progressive muscle weakness, SMA impacts bulbar and respiratory functions, with highly variable disease severity and progression.
• Phenotypes range from severe early-onset forms to later-onset presentations with loss of ambulation.

Purpose of the Study:

• To review the current therapeutic landscape for spinal muscular atrophy (SMA).
• To elucidate the efficacy and safety of emerging causal therapies for SMA.
• To focus on treatment strategies for patients with adult-onset SMA.

Main Methods:

• Review of clinical trials and basic research studies.
• Focus on patient cohorts with disease onset in adulthood.
• Analysis of therapeutic interventions targeting the genetic basis of SMA.

Main Results:

• Clinical studies demonstrate motor function improvement or stabilization with current SMA therapies.
• Therapeutic benefits must be weighed against treatment burden, especially in severely affected patients.
• Long-term efficacy and safety data for novel SMA therapeutics are still emerging.

Conclusions:

• Approved SMA therapies exhibit good efficacy across diverse severity levels and age groups.
• The absence of comparative studies necessitates individualized risk-benefit assessments for treatment selection.
• Personalized therapeutic strategies are key to managing spinal muscular atrophy effectively.